Tokushima University / Educator and Researcher Directory --- Kawanaka, Takashi

Field of Study

○	Medicine

Subject of Study

○

Book / Paper

Book:

1.	Takashi Kawanaka : 小線源治療部会ガイドラインに基づく密封小線源治療診療・物理QAマニュアル第2版, KANEHARA & CO., LTD., May 2022.

Academic Paper (Judged Full Paper):

1.	Akinari Kasai, Jinsei Miyoshi, Yasushi Sato, Koichi Okamoto, Hiroshi Miyamoto, Takashi Kawanaka, Chisato Tonoiso, Masafumi Harada, Masakazu Goto, Takahiro Yoshida, Akihiro Haga and Tetsuji Takayama : A novel CT-based radiomics model for predicting response and prognosis of chemoradiotherapy in esophageal squamous cell carcinoma., Scientific Reports, Vol.14, No.1, 2039, 2024. (Summary) No clinically relevant biomarker has been identified for predicting the response of esophageal squamous cell carcinoma (ESCC) to chemoradiotherapy (CRT). Herein, we established a CT-based radiomics model with artificial intelligence (AI) to predict the response and prognosis of CRT in ESCC. A total of 44 ESCC patients (stage I-IV) were enrolled in this study; training (n = 27) and validation (n = 17) cohorts. First, we extracted a total of 476 radiomics features from three-dimensional CT images of cancer lesions in training cohort, selected 110 features associated with the CRT response by ROC analysis (AUC ≥ 0.7) and identified 12 independent features, excluding correlated features by Pearson's correlation analysis (r ≥ 0.7). Based on the 12 features, we constructed 5 prediction models of different machine learning algorithms (Random Forest (RF), Ridge Regression, Naive Bayes, Support Vector Machine, and Artificial Neural Network models). Among those, the RF model showed the highest AUC in the training cohort (0.99 [95%CI 0.86-1.00]) as well as in the validation cohort (0.92 [95%CI 0.71-0.99]) to predict the CRT response. Additionally, Kaplan-Meyer analysis of the validation cohort and all the patient data showed significantly longer progression-free and overall survival in the high-prediction score group compared with the low-prediction score group in the RF model. Univariate and multivariate analyses revealed that the radiomics prediction score and lymph node metastasis were independent prognostic biomarkers for CRT of ESCC. In conclusion, we have developed a CT-based radiomics model using AI, which may have the potential to predict the CRT response as well as the prognosis for ESCC patients with non-invasiveness and cost-effectiveness. (Keyword) Humans / Esophageal Squamous Cell Carcinoma / Artificial Intelligence / Bayes Theorem / Esophageal Neoplasms / Radiomics / Prognosis / Chemoradiotherapy / Tomography, X-Ray Computed (Tokushima University Institutional Repository) ● Metadata: 119113 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-024-52418-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38263395 ● Search Scopus @ Elsevier (PMID): 38263395 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-024-52418-4 (Tokushima University Institutional Repository: 119113, DOI: 10.1038/s41598-024-52418-4, PubMed: 38263395)
2.	Daisuke Satoh, Motoharu Sasaki, Yuji Nakaguchi, Takeshi Kamomae, Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Yuki Kanazawa, Masataka Oita, Akimi Kajino, Akira Tsuzuki and Hitoshi Ikushima : Differences between professionals in planning treatment for patients with stage III lung cancer using treatment-planning QA software, Reports of Practical Oncology and Radiotherapy, Vol.28, No.5, 671-680, 2023. (Summary) The quality of treatment planning for stage III non-small cell lung cancer varies within and between facilities due to the different professions involved in planning. Dose estimation parameters were calculated using a feasibility dose-volume histogram (FDVH) implemented in the treatment planning quality assurance software PlanIQ. This study aimed to evaluate differences in treatment planning between occupations using manual FDVH-referenced treatment planning to identify their characteristics. The study included ten patients with stage III non-small cell lung cancer, and volumetric-modulated arc therapy was used as the treatment planning technique. Fifteen planners, comprising five radiation oncologists, five medical physicists, and five radiological technologists, developed treatment strategies after referring to the FDVH. Medical physicists had a higher mean dose at D98% of the planning target volume (PTV) and a lower mean dose at D2% of the PTV than those in other occupations. Medical physicists had the lowest irradiation lung volumes (V5 Gy and V13 Gy) compared to other professions, and radiation oncologists had the lowest V20 Gy and mean lung dose. Radiological technologists had the highest irradiation volumes for dose constraints at all indexes on the normal lung volume. The quality of the treatment plans developed in this study differed between occupations due to their background expertise, even when an FDVH was used as a reference. Therefore, discussing and sharing knowledge and treatment planning techniques among professionals is essential to determine the optimal treatment plan for each facility and patient. (Keyword) Non-small-cell lung cancer / PlanIQ / Treatment planning quality / Volumetric-modulated arc therapy (Link to Publication Site) ● Publication site (DOI): 10.5603/rpor.97511 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38179286 ● Search Scopus @ Elsevier (PMID): 38179286 ● Search Scopus @ Elsevier (DOI): 10.5603/rpor.97511 (DOI: 10.5603/rpor.97511, PubMed: 38179286)
3.	Yoshito Kusuhara, Tomoya Fukawa, Tomoharu Fukumori, Yoshiteru Ueno, Kei Daizumoto, Yutaro Sasaki, Ryotaro Tomida, Yasuyo Yamamoto, Kunihisa Yamaguchi, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima, Hiro-omi Kanayama and Masayuki Takahashi : Effect of Positive Biopsy Core Rate on Low-dose-rate Brachytherapy Outcomes in Intermediate-risk Prostate Cancer., Anticancer Research, Vol.43, No.10, 4627-4635, 2023. (Summary) Positive core ratios observed on prostate biopsy correlated with higher recurrence rates after LDR-BT. This indicates that the proportion of positive cores in the biopsy may be an important factor in predicting the likelihood of recurrence, especially for patients with GG3 PCa. (Keyword) Male / Humans / Retrospective Studies / Brachytherapy / Prostatic Neoplasms / Neoplasm Grading / Biopsy / Prostate-Specific Antigen (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.16657 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37772553 ● Search Scopus @ Elsevier (PMID): 37772553 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.16657 (DOI: 10.21873/anticanres.16657, PubMed: 37772553)
4.	Yoshiteru Ueno, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Ryotaro Tomida, Yasuyo Yamamoto, Kunihisa Yamaguchi, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima, Masayuki Takahashi and Hiro-omi Kanayama : Prostate-specific Antigen Levels Following Brachytherapy Impact Late Biochemical Recurrence in Japanese Patients With Localized Prostate Cancer., In Vivo, Vol.37, No.2, 738-746, 2023. (Summary) PSA levels at 5 years post-treatment were associated with long-term recurrence of localized prostate cancer, which can help alleviate patient anxiety concerning prostate cancer recurrence if PSA levels remain low at 5 years after LDR-BT. (Keyword) Male / Humans / Prostate-Specific Antigen / Brachytherapy / Cohort Studies / East Asian People / Prostatic Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.13136 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36881090 ● Search Scopus @ Elsevier (PMID): 36881090 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.13136 (DOI: 10.21873/invivo.13136, PubMed: 36881090)
5.	K. Ozaki, Takashi Kawanaka, Tomoya Fukawa, Kei Daizumoto, Yutaro Sasaki, Megumi Tsuda, Yoshito Kusuhara, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Appropriate management reduces radiation exposure in daily urological practice, International Journal of Urology, 2022. (Summary) To identify and raise awareness of the radiation exposure of urologists due to X-ray fluoroscopic procedures in daily practice. This was a single-center, cohort study of 30 consecutive patients who underwent periodic percutaneous or transurethral replacements of urinary tract catheters. A total of 55 replacements every 3 months with cases aligned were performed by a single urologist. The urologist's radiation exposure and the incident dose to patients per case were measured with thermoluminescent dosimeters. In the latter 3-month period, the pulse fluoroscopy condition was changed from 15 to 7.5 pulses per second, and collimation was added to the field of view. In the analysis of all patients, the use of a modified pulse rate and collimation did not affect the fluoroscopy time, but it did significantly reduce the air kerma and dose area product; in addition, with respect to the medical exposure dose during percutaneous catheter replacement, fluoroscopy time was longer, but air kerma and dose area product showed significant decreases. As with decreases in medical exposure of patients, the equivalent dose for eye lenses of the urologist decreased from 1.2 mSv in the first 3-month period to 0.2 mSv in the second 3-month period. Similarly, the exposure dose for the extremities also decreased significantly, from 33.9 mSv to 8.1 mSv. Urologists are exposed to non-negligible amounts of radiation due to fluoroscopy. Appropriate management such as modified pulse fluoroscopy condition and precautions are required. (Tokushima University Institutional Repository) ● Metadata: 118219 (Link to Publication Site) ● Publication site (DOI): 10.1111/iju.14971 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35851694 ● Search Scopus @ Elsevier (PMID): 35851694 ● Search Scopus @ Elsevier (DOI): 10.1111/iju.14971 (Tokushima University Institutional Repository: 118219, DOI: 10.1111/iju.14971, PubMed: 35851694)
6.	Akiko Abe, Masao Yuasa, Yoshie Imai, Tomohiro Kagawa, Ayuka Mineda, Masato Nishimura, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima and Takeshi Iwasa : Extreme leanness, lower skeletal muscle quality, and loss of muscle mass during treatment are predictors of poor prognosis in cervical cancer treated with concurrent chemoradiation therapy, International Journal of Clinical Oncology, Vol.27, No.5, 983-991, 2022. (Summary) Human papillomavirus vaccination is not widespread in Japan, and the low screening rates result in many cases of locally advanced cervical cancer. We investigated the prognostic significance of sarcopenia in patients with cervical cancer to guide healthcare policies to improve treatment outcomes. This retrospective study included 83 patients with cervical cancer without distant metastasis who underwent primary concurrent chemoradiotherapy between 2013 and 2018. We analyzed the indicators of physical condition and muscle quantity using the SYNAPSE VINCENT software. Muscle mass and the relationship between treatment toxicity and prognosis were evaluated. The patients' median age was 60 (range 33-80) years. Cancer stage distribution was as follows: cT2b or higher, 84.3%; N1, 65.1%; and MA, 27.7%. The overall sarcopenia (skeletal muscle index [SMI] < 38.5) rate was 30.1%, and the rate was 33.9 and 22.2% in patients aged < 64 and ≥ 65 years, respectively. No correlation was observed between clinical stage and musculoskeletal indices. Treatment resulted in decreased body weight and SMI; after treatment, the sarcopenia rate increased to 37.3%. A higher intramuscular adipose tissue content (IMAC) reduced the number of chemotherapy cycles needed. Treatment-associated SMI decreases of ≥ 7% indicated poor prognosis, with significant differences in progression-free survival and overall survival (p = 0.013 and p = 0.012, respectively). Patients who were very lean (body mass index < 18.5 kg/m) before treatment had a poor prognosis (p = 0.016 and p < 0.001). Our findings emphasize the importance of assessing original nutritional status and maintaining muscle mass and quality during the treatment of patients with cervical cancer. (Keyword) Adult / Aged / Aged, 80 and over / Chemoradiotherapy / Female / Humans / Middle Aged / Muscle, Skeletal / Papillomavirus Infections / Papillomavirus Vaccines / Prognosis / Retrospective Studies / Sarcopenia / Thinness / Uterine Cervical Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-022-02140-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35212828 ● Summary page in Scopus @ Elsevier: 2-s2.0-85125283470 (DOI: 10.1007/s10147-022-02140-w, PubMed: 35212828, Elsevier: Scopus)
7.	Kenta Kitagawa, Hitoshi Ikushima, Motoharu Sasaki, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Takaharu Kudoh, Yohsuke Kanoh and Tsuzuki Akira : Effect of dental metal artifact conversion volume on dose distribution in head-and-neck volumetric-modulated arc therapy, Journal of Applied Clinical Medical Physics, Vol.21, No.12, 253-262, 2020. (Summary) Purpose: During treatment planning for head-and-neck volumetric-modulated arc therapy (VMAT), manual contouring of the metal artifact area of artificial teeth is done, and the area is replaced with water computed tomography (CT) values for dose calculation. This contouring of the metal artifact areas, which is performed manually, is subject to human variability. The purpose of this study is to evaluate and analyze the effect of inter-observer variation on dose distribution.Methods: The subjects were 25 cases of cancer of the oropharynx for which VMAT was performed. Six radiation oncologists (ROs) performed metal artifact contouring for all of the cases. Gross tumor volume, clinical target volume, planning target volume (PTV), and oral cavity were evaluated. The contouring of the six ROs was divided into two groups, small and large groups. A reference RO was determined for each group and the dose distribution was compared with those of the other radiation oncologists by gamma analysis (GA).As an additional experiment, we changed the contouring of each dental metal artifact area, creating enlarged contours (L), reduced contours (S), and undrawn contours (N) based on the contouring by the six ROs and compared these structure-sets.Results: The evaluation of inter-observer variation showed no significant difference between the large and small groups, and the GA pass rate was 100%. Similar results were obtained comparing structure-sets L and S, but in the comparison of structure-sets L and N, there were cases with pass rates below 70%.Conclusions: The results show that the artificial variability of manual artificial tooth metal artifact contouring has little effect on the dose distribution of VMAT. However, it should be noted that the dose distribution may change depending on the contouring method in cases where the overlap between PTV and metal artifact areas is large. (Keyword) dental metal artifact / head-and-neck / volumetric-modulated arc therapy (Tokushima University Institutional Repository) ● Metadata: 115924 (Link to Publication Site) ● Publication site (DOI): 10.1002/acm2.13101 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33226172 ● Summary page in Scopus @ Elsevier: 2-s2.0-85097008301 (Tokushima University Institutional Repository: 115924, DOI: 10.1002/acm2.13101, PubMed: 33226172, Elsevier: Scopus)
8.	Chisato Tonoiso, Hitoshi Ikushima, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh, Takahiro Yoshida, Hiroshi Miyamoto, Masafumi Harada, Tetsuji Takayama and Akira Tangoku : Clinical outcomes and prognostic factors of definitive radiotherapy for esophageal cancer, The Journal of Medical Investigation : JMI, Vol.66, No.1, 2, 99-105, 2019. (Summary) Purpose To assess the treatment results of definitive radiotherapy for esophageal cancer at Tokushima University Hospital and clarify the prognostic factors. Methods Seventy consecutive patients with esophageal cancer who underwent definitive radiotherapy between May 2004 and March 2012 were included in the present study. Local control rate, overall survival rate, and radiation morbidity were examined and univariate and multivariate analyses were performed to investigate prognostic factors. Results The 5-yearoverall survival rates of stages I, II, III, and IVA were 81%, 71%, 0%, and 9%, respectively. Performance status, clinical stage, and neoadjuvant chemotherapy were significant prognostic factors. A past history of interstitial pneumonia was associated with severe radiation-induced lung injury. Conclusions Patients who underwent definitive chemoradiotherapy for esophageal cancer in stage I/II showed good prognosis. However, treatment results of the patients in stage III/IV were not satisfactory, and those who could not undergo surgery after neoadjuvant chemotherapy had the worst prognosis.J.Med.Invest.66:99-105, February, 2019. (Keyword) esophageal cancer / radiotherapy / chemoradiotherapy (Tokushima University Institutional Repository) ● Metadata: 113342 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.99 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31064964 ● Summary page in Scopus @ Elsevier: 2-s2.0-85065782310 (Tokushima University Institutional Repository: 113342, DOI: 10.2152/jmi.66.99, PubMed: 31064964, Elsevier: Scopus)
9.	Shunsuke Furutani, Hitoshi Ikushima, Motoharu Sasaki, Chisato Tonoiso, Ayaka Takahashi, Akiko Kubo, Takashi Kawanaka and Masafumi Harada : Clinical outcomes of hypofractionated image-guided multifocal irradiation using volumetric-modulated arc therapy for brain metastases., Journal of Radiation Research, Vol.60, No.1, 134-141, 2019. (Summary) Volumetric-modulated arc therapy (VMAT) can be used to design hypofractionated radiotherapy treatment plans for multiple brain metastases. The purpose of this study was to evaluate treatment outcomes of hypofractionated image-guided multifocal irradiation using VMAT (HFIGMI-VMAT) for brain metastases. From July 2012 to December 2016, 67 consecutive patients with 601 brain metastases were treated with HFIGMI-VMAT at our institution. The prescribed dose was 50 Gy to a 95% volume of the planning target volume in 10 fractions. Fifty-five of the 67 patients had non-small-cell lung cancer, and the remaining 12 had other types of cancer. The median number of brain metastases was five, and the median maximum diameter was 1.2 cm. The median duration of follow-up was 12.0 months (range, 1.9-44.8 months), and the median survival time 18.7 months. Four patients with six lesions had local recurrences. The local control rate in the 64 assessed patients was 98.4% and 95.3% at 6 and 12 months, respectively (three died before assessment). The local control rate for the 572 assessed lesions was 99.8% and 99.3% at 6 and 12 months, respectively. Thirty-nine patients developed distant brain metastases, the distant brain control rate being 59.7% and 40.5% at 6 and 12 months, respectively. Acute toxicities were generally mild (Grade 1-2). Three patients (4.5%) developed radiation necrosis requiring corticosteroid therapy. The HFIGMI-VMAT technique with flat dose delivery was well tolerated and achieved excellent local control. This technique is a promising treatment option for patients with multiple and large brain metastases. (Tokushima University Institutional Repository) ● Metadata: 115535 (Link to Publication Site) ● Publication site (DOI): 10.1093/jrr/rry091 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30445426 ● Search Scopus @ Elsevier (PMID): 30445426 ● Search Scopus @ Elsevier (DOI): 10.1093/jrr/rry091 (Tokushima University Institutional Repository: 115535, DOI: 10.1093/jrr/rry091, PubMed: 30445426)
10.	Hiroyuki Ono, Taichi Murakami, Akira Mima, Eriko Shibata, Masanori Tamaki, Sakiya Yoshimoto, Sayo Ueda, Fumi Kishi, Seiji Kishi, Takashi Kawanaka, Motokazu Matsuura, Kojiro Nagai, Hideharu Abe, Masashi Harada and Toshio Doi : Successful treatment of highly advanced immunoglobulin G4-related kidney disease presenting renal mass-like regions with end-stage kidney failure: a case study., BMC Nephrology, Vol.18, No.1, 261, 2017. (Summary) In immunoglobulin G4-related kidney disease with severe kidney failure, radiological findings should be carefully examined. In addition, renal prognosis may be good despite highly advanced tubulointerstitial nephritis and fibrosis. (Tokushima University Institutional Repository) ● Metadata: 114372 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12882-017-0676-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28774276 ● Search Scopus @ Elsevier (PMID): 28774276 ● Search Scopus @ Elsevier (DOI): 10.1186/s12882-017-0676-5 (Tokushima University Institutional Repository: 114372, DOI: 10.1186/s12882-017-0676-5, PubMed: 28774276)
11.	Hidehisa Mori, Tomoharu Fukumori, KEI DAIZUMOTO, MEGUMI TSUDA, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Hiro-omi Kanayama : Predictive Factors for Prolonged Urination Disorder After Permanent 125I Brachytherapy for Localized Prostate Cancer, In Vivo, Vol.31, No.4, 755-761, 2017. (Summary) We assessed the change in LUTS after prostate brachytherapy to reveal factors for prolonged urination disorder. Four hundred and four patients received prostate brachytherapy at our institution and were followed-up for at least 2 years. We evaluated the correlation of mean IPSS changes and clinical factors. Using multivariate analysis, we also evaluated clinical factors with potential to delay IPSS resolution. In cases with prostate volume more than 30 cm, radiation dose to 90% of prostate volume (D90) more than 160 Gy, and radiation dose to 30% of the urethral volume (UD30) more than 240 Gy, mean IPSS levels were significantly higher, even 30 months after treatment. On multivariate analysis, baseline IPSS more than 8 points and D90 more than 160 Gy were significant predictors for delayed IPSS resolution. Our data suggest that higher baseline IPSS and higher D90 were predictors for prolonged urination disorder. (Keyword) Aged / Aged, 80 and over / Brachytherapy / Humans / Iodine Radioisotopes / male / Middle Aged / Prostate / Prostate-Specific Antigen / Prostatic Neoplasms / Urination Disorders (Tokushima University Institutional Repository) ● Metadata: 113626 (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.11127 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28652453 ● Summary page in Scopus @ Elsevier: 2-s2.0-85028539877 (Tokushima University Institutional Repository: 113626, DOI: 10.21873/invivo.11127, PubMed: 28652453, Elsevier: Scopus)
12.	Takaharu Kudoh, Hitoshi Ikushima, Keiko Kudoh, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo, Natsumi Takamaru, Tetsuya Tamatani and Youji Miyamoto : Effectiveness of Newly Developed Water-Equivalent Mouthpiece during External Beam Radiotherapy for Oral Cancer, Ann Carcinog, Vol.2, No.1, 2017. (Tokushima University Institutional Repository) ● Metadata: 113606 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570009752882329984 (Tokushima University Institutional Repository: 113606, CiNii: 1570009752882329984)
13.	Hiromichi Ishiyama, Takefumi Satoh, Atsunori Yorozu, Shiro Saito, Masaaki Kataoka, Katsuyoshi Hashine, Ryuji Nakamura, Susumu Tanji, Koji Masui, Koji Okihara, Toshio Ohashi, Tetsuo Momma, Manabu Aoki, Kenta Miki, Masako Kato, Masashi Morita, Norihisa Katayama, Yasutomo Nasu, Takashi Kawanaka, Tomoharu Fukumori, Fumitaka Ito, Ryoichi Shiroki, Yuji Baba, Akito Inadome, Yasuo Yoshioka, Hitoshi Takayama and Kazushige Hayakawa : Multi-institutional retrospective analysis of learning curves on dosimetry and operation time before and after introduction of intraoperatively built custom-linked seeds in prostate brachytherapy., Journal of Radiation Research, Vol.57, No.1, 68-74, 2015. (Summary) This multi-institutional retrospective analysis examined learning curves for dosimetric parameters and operation time after introduction of intraoperatively built custom-linked (IBCL) seeds. Data from consecutive patients treated with seed implantation before and after introduction of IBCL seeds (loose seed, n = 428; IBCL seed, n = 426) were collected from 13 centers. Dose-volume histogram parameters, operation times, and seed migration rates were compared before and after introduction of IBCL seeds. At the 1-month CT analysis, no significant differences were seen in dose to 90% of prostate volume between before and after IBCL seed introduction. No learning curve for dosimetry was seen. Prostate and rectal volume receiving at least 150% of prescription dose (V150 and RV150) were higher in the loose-seed group than in the IBCL-seed group. Operation time was extended by up to 10 min when IBCL seeds were used, although there was a short learning curve of about five patients. The percentage of patients with seed migration in the IBCL-seed group was one-tenth that in the loose-seed group. Our study revealed no dosimetric demerits, no learning curve for dosimetry, and a slightly extended operation time for IBCL seeds. A significant reduction in the rate of seed migration was identified in the IBCL-seed group. (Keyword) Aged / Brachytherapy / Humans / Intraoperative Care / Learning Curve / Male / Operative Time / Prostate / Prostatic Neoplasms / Radiotherapy Dosage / Radiotherapy Planning, Computer-Assisted / Retrospective Studies / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1093/jrr/rrv065 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26494116 ● Summary page in Scopus @ Elsevier: 2-s2.0-84959863886 (DOI: 10.1093/jrr/rrv065, PubMed: 26494116, Elsevier: Scopus)
14.	Tomokazu Senzaki, Tomoharu Fukumori, Hidehisa Mori, Yoshito Kusuhara, Masatsugu Komori, Junichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Hiro-omi Kanayama : Clinical Significance of Neoadjuvant Combined Androgen Blockade for More Than Six Months in Patients with Localized Prostate Cancer Treated with Prostate Brachytherapy., Urologia Internationalis, Vol.95, No.4, 457-464, 2015. (Summary) The aim of this study is to clarify the clinical significance of neoadjuvant combined androgen blockade (CAB) for ≥ 6 months in patients with localized prostate cancer. A total of 431 patients with localized prostate cancer who underwent prostate brachytherapy (BT) with or without neoadjuvant CAB for ≥ 6 months with mean follow-up time of 64.6 months (range 24-108 months) were evaluated retrospectively. Of those 431, 232 patients received BT in combination with neoadjuvant CAB for ≥ 6 months. Biochemical recurrence-free rates (BRFRs) in 364 patients with at least 3 years of follow-up were evaluated by log-rank test. BRFR in patients with low-, intermediate- and high-risk prostate cancer were 98.1, 94.2 and 89.1%, respectively. In patients with intermediate-risk prostate cancer only, neoadjuvant CAB was significantly associated with BRFR (p = 0.0468). Especially in patients with intermediate-risk prostate cancer with radiation dose received by 90% of the prostate (D90) < 180 Gy, neoadjuvant CAB exerted a favorable impact on BRFR (p = 0.0429). On multivariate analyses, neoadjuvant CAB and D90 were independent predictors of BRFR (p = 0.0061 and p < 0.0001, respectively). Neoadjuvant CAB for ≥ 6 months has a favorable impact on BRFR in patients with intermediate-risk prostate cancer, particularly in patients with relatively low radiation doses of D90. (Link to Publication Site) ● Publication site (DOI): 10.1159/000439573 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26461847 ● Search Scopus @ Elsevier (PMID): 26461847 ● Search Scopus @ Elsevier (DOI): 10.1159/000439573 (DOI: 10.1159/000439573, PubMed: 26461847)
15.	Akiko Mino, Kayo Shinomiya, Takashi Kawanaka, Mika Sakaki, 吉本聖, 坂本佳也, 荒瀬友子 and Yoshinori Mitamura : Palliative radiotherapy was effective in a case of sebaceous carcinoma of presumed lacrimal gland origin, Japanese Journal of Clinical Ophthalmology, Vol.69, No.3, 397-402, 2015. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390283684920771200 ● Summary page in Scopus @ Elsevier: 2-s2.0-84928953575 (CiNii: 1390283684920771200, Elsevier: Scopus)
16.	Bado Ryota, Hitoshi Ikushima, Takashi Kawanaka, Takaharu Kudoh, Motoharu Sasaki, Masahide Tominaga, Taro Kishi, Shunsuke Furutani, Akiko Kubo and Koichi Tamura : Changes of tumor and normal structures of the neck during radiation therapy for head and neck cancer requires adaptive strategy., The Journal of Medical Investigation : JMI, Vol.60, No.1,2, 46-51, 2013. (Summary) The treatment period over which radiation therapy is administered extends over several weeks. Since tumor shrinkage in response to radiation therapy and weight loss due to radiation-induced mucositis may impact on the dose distribution in both target and organ at risk in patients with head and neck cancer, the anatomical changes of tumor and neck volumes during this period should be taken into consideration. We investigated the anatomical changes that occurred in the target and normal structure of the neck during radiation therapy for pharyngeal cancer, and evaluated the necessity of an adaptive strategy. Ten patients with pharyngeal cancer who underwent radical chemoradiation therapy using 3-dimensional conformal radiation therapy RT (66-70 Gy in 33-35 fractions) between April 2009 and September 2010 were enrolled in the study. Patients underwent CT scans every week during their course of treatment. We analyzed the CT data in the radiation treatment planning system and measured changes of tumor, organ at risk, and neck volume. Gross tumor volume (GTV) was rapidly reduced by 28% of the original volume on average in the first 3 weeks. The right and left submandibular glands volume decreased to 70% and 63% of their initial volumes on average, respectively. The volume of the neck in the radiation fields decreased to 89% of its initial volume on average by the sixth week mainly caused by body weight loss due to acute radiation morbidity. Considerable anatomical change in the radiation filed that will affect dose distribution of the target and organ at risk was observed during radiation therapy for head and neck cancer. (Keyword) adaptive strategy / chemoradiotherapy / head and neck cancer (Tokushima University Institutional Repository) ● Metadata: 106041 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.60.46 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23614911 ● Search Scopus @ Elsevier (PMID): 23614911 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.60.46 (Tokushima University Institutional Repository: 106041, DOI: 10.2152/jmi.60.46, PubMed: 23614911)
17.	Hai Lan, Hiromu Nishitani, Sadamitsu Nishihara, Junji Ueno, Shoichiro Takao, Seiji Iwamoto, Takashi Kawanaka, Mawlan MAHMUT and Si QINGGE : Using the MDCT thick slab MinIP method for the follow-up of pulmonary emphysema, The Journal of Medical Investigation : JMI, Vol.58, No.3, 175-179, 2011. (Summary) The purpose of this study was to evaluate the usefulness of thick slab minimum intensity projection (MinIP) as a follow-up method in patients with pulmonary emphysema. This method was used to determine the presence or absence of changes over time in the lung field based on multi-detector-row CT (MDCT) data. Among patients diagnosed with pulmonary emphysema who underwent 16-MDCT (slice thickness, 1 mm) twice at an interval of 6 months or more, 12 patients without changes in the lung field and 14 with clear changes in the lung field were selected as subjects. An image interpretation experiment was performed by five image interpreters. Pulmonary emphysema was followed up using two types of thick slab MinIP (thick slab MinIP 1 and 2) and multi-planar reformation (MPR), and the results of image interpretation were evaluated by receiver operating characteristic (ROC) analysis. In addition, the time required for image interpretation was compared among the three follow-up methods. The area under the ROC curve (Az) was 0.794 for thick slab MinIP 1, 0.778 for the thick slab MinIP 2, and 0.759 for MPR, showing no significant differences among the three methods. Individual differences in each item were significantly more marked for MPR than for thick slab MinIP. The time required for image interpretation was around 18 seconds for thick slab MinIP 1, 11 seconds for thick slab MinIP 2, and approximately 127 seconds for MPR, showing significant differences among the three methods. There were no significant differences in the results of image interpretation regarding the presence or absence of changes in the lung fields between thick slab MinIP and MPR. However, thick slab MinIP showed a shorter image interpretation time and smaller individual differences in the results among image interpreters than MPR, suggesting the usefulness of this method for determining the presence or absence of changes with time in the lung fields of patients with pulmonary emphysema. (Keyword) Follow-Up Studies / Humans / Multidetector Computed Tomography / Pulmonary Emphysema / Radiographic Image Interpretation, Computer-Assisted (Tokushima University Institutional Repository) ● Metadata: 83831 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.58.175 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21921417 ● Summary page in Scopus @ Elsevier: 2-s2.0-80052759824 (Tokushima University Institutional Repository: 83831, DOI: 10.2152/jmi.58.175, PubMed: 21921417, Elsevier: Scopus)
18.	Takaharu Kudoh, Hitoshi Ikushima, Keiko Kudoh, Reiko Tokuyama, Kyosuke Osaki, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo, Hiromu Nishitani and Eiichi Honda : High-dose-rate brachytherapy for patients with maxillary gingival carcinoma using a novel customized intraoral mold technique., Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, Vol.109, No.2, e102-8, 2010. (Summary) OBJECTIVE: The purpose of this study was to introduce a novel customized intraoral mold treatment for maxillary gingival carcinoma (UGC). STUDY DESIGN: Two patients with UGC were treated as salvage therapy using this technique. The mold was designed to keep normal soft tissues adjacent to the tumor away from the radioactive source as much as possible, and it was shielded by lead. The radiation dose on the buccal mucosa and tongue was measured at the inner and outer surfaces of the intraoral mold before starting high-dose-rate brachytherapy by the remote afterloading system, and was reduced to almost one tenth. RESULTS: The patient had no recurrence and no severe adverse effects on the normal soft tissue adjacent to the tumor until the end of the follow-up period. CONCLUSION: High-dose-rate brachytherapy using the novel customized intraoral mold might be a treatment option of not only salvage therapy, but definitive therapy of UGC. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.tripleo.2009.10.019 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20123391 ● Search Scopus @ Elsevier (PMID): 20123391 ● Search Scopus @ Elsevier (DOI): 10.1016/j.tripleo.2009.10.019 (DOI: 10.1016/j.tripleo.2009.10.019, PubMed: 20123391)
19.	Akiko Kubo, Kyosuke Osaki, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Hiromu Nishitani : Risk factors for radiation pneumonitis caused by whole breast irradiation following breast-conserving surgery., The Journal of Medical Investigation : JMI, Vol.56, No.3,4, 99-110, 2009. (Summary) We evaluated risk factors of radiation pneumonitis (RP) after whole breast irradiation following breast-conserving surgery. Four hundred and seventy-two cases underwent whole breast irradiation with tangential field following breast-conserving surgery in our hospital, between January 2005 and April 2007. Of these cases, we performed statistical analyses for 423 breasts of 413 patients, using a pulmonary dose-volume histogram. Patient characteristics, treatment regimens and irradiation methods were included as variables in the analyses on risk factors of RP. As a result, 89 breasts of 84 cases (21%) were diagnosed with RP. The version 3.0 of the NCI Common Terminology Criteria for Adverse Events was used to evaluate the grade of pneumonitis: 77 cases (18.2%) were diagnosed as Grade 1 RP, 10 cases (2.3%) as Grade 2, and 2 cases (0.5%) as Grade 3. Multivariate analysis indicated that the significant risk factors for RP were central lung distance (CLD) (>1.8 cm) and the short axis length of the radiation field. The incidence of radiation-induced bronchiolitis obliterans organizing pneumonia (BOOP) syndrome significantly correlated only with CLD. The lung volume within the radiation field was shown to be a significant risk factor for RP and radiation-induced BOOP syndrome. (Keyword) Adult / Aged / Aged, 80 and over / Breast Neoplasms / Combined Modality Therapy / Cryptogenic Organizing Pneumonia / Dose-Response Relationship, Radiation / Female / Humans / Lung / Mastectomy, Segmental / Middle Aged / Postoperative Complications / Radiation Pneumonitis / Risk Factors / Young Adult (Tokushima University Institutional Repository) ● Metadata: 111315 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.56.99 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19763021 ● Search Scopus @ Elsevier (PMID): 19763021 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.56.99 (Tokushima University Institutional Repository: 111315, DOI: 10.2152/jmi.56.99, PubMed: 19763021)
20.	Hitoshi Ikushima, Seiji Iwamoto, Kyohsuke Osaki, Shunsuke Furutani, Kyoh Yamashita, Takashi Kawanaka, Akiko Kubo, Yoshihiro Takegawa, Takaharu Kudoh, Hiroomi Kanayama and Hiromu Nishitani : Effective bladder preservation strategy with low-dose radiation therapy and concurrent intraarterial chemotherapy for muscle-invasive bladder cancer., Radiation Medicine, Vol.26, No.3, 156-163, 2008. (Summary) PURPOSE: The aim of this study was to evaluate retrospectively the toxicity and response, bladder preservation, and survival of patients with muscle-invasive bladder cancer treated with multimodality therapy consisting of low-dose radiation therapy (RT) and concurrent intraarterial chemotherapy (IACT). METHODS AND MATERIALS:. Between November 1999 and July 2005, a total of 27 consecutive, previously untreated patients with muscle-invasive bladder cancer underwent transurethral bladder tumor resection followed by concurrent low-dose RT and IACT. Patients who achieved a complete response (CR) were followed up closely without further therapy, and patients who did not achieve a CR underwent further treatment. RESULTS: Complete response was achieved in 22 of 27 patients (81%). Of these 22 patients, 7 developed recurrences, and 3 died of their disease. In five patients who did not achieve CR, one died from bone metastases. The 3-year overall survival rate was 81%, with a median follow-up time of 27 months; and 22 of 27 patients (81%) with a preserved bladder were tumor-free at the last follow-up. Three patients (11%) developed grade 3 acute hematological toxicity. CONCLUSION: Multimodality therapy consisting of low-dose RT and concurrent IACT for muscle-invasive bladder cancer can achieve survival rates similar to those in patients treated with radical cystectomy, with successful bladder preservation and minimal adverse effects. (Keyword) Antineoplastic Combined Chemotherapy Protocols / Combined Modality Therapy / Cystectomy / Female / Humans / Infusions, Intra-Arterial / Male / Neoplasm Invasiveness / Neoplasm Recurrence, Local / Radiotherapy Dosage / Retrospective Studies / Survival Rate / Treatment Outcome / Urinary Bladder Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1007/s11604-007-0211-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18683571 ● Search Scopus @ Elsevier (PMID): 18683571 ● Search Scopus @ Elsevier (DOI): 10.1007/s11604-007-0211-x (DOI: 10.1007/s11604-007-0211-x, PubMed: 18683571)
21.	Takashi Kawanaka, Akiko Kubo, Hitoshi Ikushima, Toshiaki Sano, Yoshihiro Takegawa and Hiromu Nishitani : Prognostic significance of HIF-2alpha expression on tumor infiltrating macrophages in patients with uterine cervical cancer undergoing radiotherapy., The Journal of Medical Investigation : JMI, Vol.55, No.1-2, 78-86, 2008. (Summary) Hypoxia-inducible factor (HIF)-2alpha, a basic helix-loop-helix (bHLH)-PAS protein, is the principal regulator of the hypoxic transcriptional response. An immunohistochemical study reported strong HIF-2alpha expression in the cytoplasm of tumor infiltrative macrophages (TIMs). Thus we assessed the expression of HIF-2alpha in human cervical cancer tissue before radiation therapy and its relationship to the clinical outcome. Seventy three patients with histologically proven primary advanced squamous cell carcinoma of the uterine cervix underwent radiotherapy in Tokushima University Hospital after biopsy specimens were taken. Among 73 specimens stained for HIF-2alpha, 53 (72.6%) exhibited HIF-2alpha immunoreactivity in the TIMs. In only 5 of 73 cases, HIF-2alpha immunoreactivity was observed in the nuclei of tumor cells. The HIF-2alpha positive cell count ratio in TIMs was associated with disease-free survival (DFS) with the worst DFS (p=0.024) being in cases in the group with a high positive cell count ratio. A high HIF-2alpha positive cell count ratio in TIMs increased the risk of local recurrence (p=0.0142). These findings might suggest that the ratio of the HIF-2alpha positive cell in TIMs may be a new predictive indicator for prognosis before radiation therapy for uterine cervical cancer. (Keyword) Adult / Aged / Aged, 80 and over / Basic Helix-Loop-Helix Transcription Factors / Carcinoma, Squamous Cell / Female / Gene Expression Regulation, Neoplastic / Humans / Macrophages / Middle Aged / Predictive Value of Tests / Prognosis / Retrospective Studies / Tumor Markers, Biological / Uterine Neoplasms (Tokushima University Institutional Repository) ● Metadata: 110842 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.55.78 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18319549 ● Search Scopus @ Elsevier (PMID): 18319549 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.55.78 (Tokushima University Institutional Repository: 110842, DOI: 10.2152/jmi.55.78, PubMed: 18319549)
22.	Yoshihiro Takegawa, Hitoshi Ikushima, Kyosuke Osaki, Shunsuke Furutani, Takashi Kawanaka, Takaharu Kudoh and Masafumi Harada : Can Kampo Therapy prolong the life of cancer patients?, The Journal of Medical Investigation : JMI, Vol.55, No.1,2, 99-105, 2008. (Summary) Our policy regarding the performance of radiotherapy to squamous cell carcinoma of the uterine cervix has not changed since 1969. We have already reported the treatment results which were as good as those from other institutions. Since 1978, Kampo therapy was first introduced in the treatment of cancer patients in dealing with problems such as the side effects of radiotherapy and chemotherapy and various types of general malaise. We analyzed our treatment results in order to re-evaluate the chemo-radiotherapy in combination with Kampo. Survival rates for 5, 10 and 15 years, respectively, were 90.9%, 71.6% and 71.6% for Stage IB, 78.9%, 61.8% and 41.8% for Stage II, 62.3%, 49.1% and 41.2% for Stage III and 53.1%, 36.5% and 16.7% for Stage IV. The Kampo significantly extended the survival of patients with uterine cervical cancer. We intend to perform further research with more patients to explore how this therapy contributes to the prolonging of patients survival. (Keyword) Adult / Aged / Aged, 80 and over / Carcinoma, Squamous Cell / Combined Modality Therapy / Drugs, Chinese Herbal / Female / Follow-Up Studies / Humans / Medicine, Kampo / Middle Aged / Neoplasm Staging / Phytotherapy / Quality of Life / Retrospective Studies / Survival Rate / Time Factors / Treatment Outcome / Uterine Cervical Neoplasms (Tokushima University Institutional Repository) ● Metadata: 110845 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.55.99 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18319551 ● Search Scopus @ Elsevier (PMID): 18319551 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.55.99 (Tokushima University Institutional Repository: 110845, DOI: 10.2152/jmi.55.99, PubMed: 18319551)
23.	Hitoshi Ikushima, Yoshihiro Takegawa, Kyohsuke Osaki, Shunsuke Furutani, Kyoh Yamashita, Takashi Kawanaka, Akiko Kubo, Takaharu Kudoh and Hiromu Nishitani : Radiation therapy for cervical cancer in the elderly, Gynecologic Oncology, Vol.107, No.2, 339-343, 2007. (Summary) To evaluate the long-term results of radical radiation therapy (RT) for cervical cancer in elderly patients. We reviewed the clinical records of 727 patients with cervical cancer who underwent radical RT at the Tokushima University Hospital and compared the treatment results of three age groups: </=64 years (younger group [YG], 337 patients), 65-74 years (young-old group [YOG], 258 patients), and >/=75 years (older group [OG], 132 patients). At the last follow-up, 155 YG (46%), 77 YOG (30%), and 48 OG patients (36%) had died of cervical cancer; the median follow-up periods were 82, 87, and 68 months, respectively. The 5-/10-year disease-specific survival rates were 60%/52% in YG, 76%/68% in YOG, and 66%/57% in OG. Differences between OG and the other groups were not significant. The 5-/10-year disease-specific survival rate of YOG was significantly superior to that of YG (p<0.001). Clinical stage was the only significant prognostic variable (p<0.001). Late radiation morbidity of grades 2-4 in the bladder and/or rectum occurred in 22% of YG, 31% of YOG, and 8% of OG patients. RT was well tolerated in elderly patients, and age was not a significant prognostic factor. In the management of cervical cancer, advanced age is not a contraindication to radical RT. (Keyword) Adenocarcinoma / Adult / Age Factors / Aged / Aged, 80 and over / Brachytherapy / Carcinoma, Squamous Cell / Chemotherapy, Adjuvant / Disease-Free Survival / Female / Humans / Japan / Medical Records / Middle Aged / Multivariate Analysis / Neoplasm Staging / Prognosis / Radiation Injuries / Radiotherapy / Retrospective Studies / Risk Factors / Treatment Outcome / Uterine Cervical Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ygyno.2007.07.058 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17707075 ● Search Scopus @ Elsevier (PMID): 17707075 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ygyno.2007.07.058 (DOI: 10.1016/j.ygyno.2007.07.058, PubMed: 17707075)
24.	Hitoshi Ikushima, Kyousuke Osaki, Shunsuke Furutani, Kyou Yamashita, Takashi Kawanaka, Yoshiomi Kishida, Seiji Iwamoto, Yoshihiro Takegawa, Takaharu Kudoh and Hiromu Nishitani : Chemoradiation Therapy for Cervical Cancer:Toxicity of Concurrent Weekly Cisplatio, Radiation Medicine, Vol.24, No.2, 115-121, 2006. (Summary) To retrospectively evaluate the toxicity of concurrent weekly cisplatin and radiation therapy (RT) for locally advanced cervical cancer. Between April 2001 and December 2004, 21 consecutive previously untreated patients with locally advanced cervical cancer were treated with concurrent chemoradiation therapy (CCRT) at the Tokushima University Hospital. Clinical stages were II: 5, III: 15, IVA: 1. External beam radiation therapy (EBRT) was delivered with 10 MV X-rays, 2 Gy fraction per day; total dose to the whole pelvis was 50 Gy. Iridium-192 high-dose-rate (HDR) intracavitary radiation therapy was performed with 10-30 Gy (median, 24 Gy) targeted at point A. Concurrent chemotherapy consisted of cisplatin, administered weekly at a dose of 40 mg/m2 for patients who were younger than 65 years and 30 mg/m2 for those 65 years or over. A maximum single dose of cisplatin, up to 70 mg/body, was administered in 5 cycles during EBRT. A total of 86 cycles of cisplatin were administered to the 21 patients, with a median of 4 cycles (range, 2-5). Severe hematological toxicity occurred in 18 patients (86%), including grade 3 in 17 patients (81%) and grade 4 in one patient (4.8%). Moderate or severe gastrointestinal toxicity occurred in 11 patients (52%), including grade 2 in 10 patients (48%) and grade 3 in one patient (4.8%). The grades of hematological toxicity were significantly greater in the 40 mg/m2 group than in the 30 mg/m2 group. All of the patients who were administered 40 mg/m2 of cisplatin developed grade 3 or greater hematological toxicity, including one patient with grade 4 toxicity. In the 30 mg/m2 group, 3 of 10 patients developed less than grade 3 toxicity, and all patients completed radiation therapy without interruption. The incidence of severe acute hematological toxicity was significantly higher in this study than in previously reported randomized controlled trials (RCTs), especially in the group of 40 mg/m2 cisplatin. A dose of 30 mg/m2 of cisplatin was considered to be feasible in weekly cisplatin and radiation therapy. (Keyword) radiation therapy / concurrent chemotherapy / cervical cancer / acute toxicity (Link to Publication Site) ● Publication site (DOI): 10.1007/BF02493277 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16715672 ● Search Scopus @ Elsevier (PMID): 16715672 ● Search Scopus @ Elsevier (DOI): 10.1007/BF02493277 (DOI: 10.1007/BF02493277, PubMed: 16715672)

Proceeding of International Conference:

1.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Hitoshi Ikushima, Masafumi Harada and Kawanaka Taeko : Initial Experience and Evaluation of Safety in Hypofractionated Accelerated Partial Breast irradiation using a Brachytherapy Multi-catheter Approach, FARO & KOSRO 2023, Seul, Korea, Oct. 2023.
2.	Takashi Kawanaka, Chisato Tonoiso, Akiko Kubo and Hitoshi Ikushima : Compatibility of SAVI applicator and resection cavity underwent cylindrical breast resection for early-stage breast cancer and its solution: initial experience of Hybrid APBI, RSNA2021, Chicago, Nov. 2020.
3.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Chisato Tonoiso, Hitoshi Ikushima and Masafumi Harada : Long-Term Outcome of Low-Dose Rate Brachytherapy with I-125 Seeds as a Monotherapy for High-Risk Prostate Cancer Patients: A Propensity Score-Matched Analysis, RSNA2018, Nov. 2018.
4.	Chisato Tonoiso, Hitoshi Ikushima, Akihiro Haga, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo, Masato Nishimura, Akiko Abe, Minoru Irahara and Masafumi Harada : Investigation of prognostic factors of cervical cancer using pre-treatment MRI images, The 2018 International Gynecologic Cancer Society Meeting, Sep. 2018.
5.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : Low-Dose Rate Brachytherapy with I-125 Seeds as a Monotherapy for High-Risk Prostate Cancer Patient: A Japanese Single Institutional Study, ASTRO's 59th Annual Meeting, San Diego, Oct. 2017. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijrobp.2017.06.1191 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijrobp.2017.06.1191 (DOI: 10.1016/j.ijrobp.2017.06.1191)
6.	Takashi Kawanaka, Shunsuke Furutani, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : Long-Term Outcome of Low-Dose Rate Brachytherapy with I-125 Seeds as a Monotherapy for High-Risk Prostate Cancer Patients, 2017 ABS Annual Conference, Boston, Apr. 2017.
7.	Shunsuke Furutani, Hitoshi Ikushima, Takashi Kawanaka, Akiko Kubo, Ayaka Takahashi, Kanako Miyamoto, Yuta Arai, Saki Nagase and Masafumi Harada : Clinical Outcomes of Fractionated Stereotactic Radiotherapy using Volumetric Modulated Arc Therapy for Multiple Brain Metastases, 58th Annual meeting of the American society for therapeutic radiology and oncology, Boston, Sep. 2016.
8.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : Impact of Salvage Chemoradiation Therapy With Triple-Drug Combination(Docetaxel,5-FU, and CDDP)for Postoperative Locoregional Recurrence of Esophageal Cancer, 58th Annual meeting of the American society for therapeutic radiology and oncology, Boston, Sep. 2016.
9.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : Long-term Outcome of I125 Low-dose-rate Brachytherapy for Clinically Localized Prostate Cancer at Single University Hospital,Which Is One of The Initial Institutions Using I125 Low-dese-rate Brachytherapy in Japan, 2016 ABS Annual Meeting(World Congress of Brachytherapy), San Francisco, Jun. 2016.
10.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : Salvage chemoradiation therapy with triple-drug combination (Docetaxel, 5-FU and CDDP) for postoperative locoregional recurrence of esophageal cancer, 56th annual meeting of ASTRO, San Francisco, Sep. 2014.
11.	Akiko Kubo, Hitoshi Ikushima, Shunsuke Furutani, Takashi Kawanaka and Masafumi Harada : Contribution of imaging in diagnosis of local recurrence after radiation therapy for cervical cancer, San Francisco, Sep. 2014.
12.	Takashi Kawanaka : Prognostic Significance of UROD Expression on Cervical Cancer with Radiotherapy., 55th American Society for Radiation Oncology Annual meeting, Atlanta, Sep. 2013.
13.	Shunsuke Furutani, Hitoshi Ikushima, Kyosuke Osaki, Kyo Yamashita, Takashi Kawanaka, Seiji Iwamoto, Akiko Kubo, Yoshihiro Takegawa and Hiromu Nishitani : Intraarterial chemotherapy and concurrent radiation for locally advanced bladder cancer, 49th Annual meeting of the American society for therapeutic radiology and oncology, Los Angeles, Oct. 2007.

Proceeding of Domestic Conference:

1.	Akiko Kubo, Chisato Tonoiso, Takashi Kawanaka and Hitoshi Ikushima : 当院における高リスク前立腺癌患者に対する外照射併用小線源治療の治療成績, 第141回日本医学放射線学会中国四国地方会, Dec. 2024.
2.	Akiko Kubo, Hitoshi Ikushima, Chisato Tonoiso, Takashi Kawanaka and Masafumi Harada : 子宮頸癌に対する2種類の組織内併用腔内照射アプリケータ使用の初期使用経験, 日本放射線腫瘍学会第37回学術大会, Nov. 2024.
3.	Chisato Tonoiso, Takashi Kawanaka, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : 膀胱癌に対する動注化学療法併用放射線治療の治療成績, 日本放射線腫瘍学会第37回学術大会, Nov. 2024.
4.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Hitoshi Ikushima and Masafumi Harada : Multicatheter法によるVAPBIの短期治療成績と有害事象の評価, 日本放射線腫瘍学会第37回学術大会, Nov. 2024.
5.	岸本悠斗, Motoharu Sasaki, Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Takaharu Kudoh and Hitoshi Ikushima : F-18 FDG-PETによる子宮頸癌放射線治療後の予後予測, 日本放射線腫瘍学会第37回学術大会, Nov. 2024.
6.	Youichi Otomi, Takanori BANDOH, Hideki Otsuka, Ryosuke Kasai, Tamaki Otani, Yamato Kunikane, 岡田直子, Tomoki MATSUSHITA, Takashi Kawanaka, Takayoshi Shinya and Masafumi Harada : Clinical practice of peptide receptor radionuclide therapy in Tokushima University Hospital, 第64回日本核医学会学術総会/第44回日本核医学技術学会総会学術大会, Nov. 2024.
7.	Takashi Kawanaka, Hitoshi Ikushima, Masato Nishimura, Akiko Abe, Akiko Kubo and Chisato Tonoiso : 18=F Fluorodeoxyglucose Positron Emission Tomographyによる子宮頸癌放射線治療後の予後予測, 第66回日本婦人科腫瘍学会学術講演会, Jul. 2024.
8.	Chisato Tonoiso, Hitoshi Ikushima, Akihiro Haga, Motoharu Sasaki, Takashi Kawanaka, Akiko Kubo, Masato Nishimura and Akiko Abe : 子宮頸癌リンパ節転移の術前予測におけるMRIレディオミクス解析の有用性, 第66回日本婦人科腫瘍学会学術講演会, Jul. 2024.
9.	Takaharu Kudoh, Keiko Kudoh, Natsumi Takamaru, Akira Takahashi, Naito Kurio, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Youji Miyamoto and Hitoshi Ikushima : Unilateral Neck Volumetric-Modulated Arc Therapy, 日本歯科放射線学会第64回学術大会, May 2024.
10.	Takashi Kawanaka, Chisato Tonoiso, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : 小線源治療によるAPBIを地域連携で行うBra-Shiの取り組み, 日本放射線腫瘍学会小線源治療部会第26回学術大会, May 2024.
11.	Akiko Kubo, Chisato Tonoiso, Takashi Kawanaka, 上野恵輝, Yoshito Kusuhara and Hitoshi Ikushima : 当院における高リスク前立腺癌患者に対する外照射併用小線源治療, 日本放射線腫瘍学会小線源治療部会第26回学術大会, May 2024.
12.	寺澤翠, Hiroki Bandoh, Keiko Haji, Hiroto Yoneda, Hirokazu Ogino, 岡田直子, Takashi Kawanaka, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : ペプチド受容体放射性核種療法が奏効した左下葉原発進行期非定型カルチノイドの1例, 第69回日本呼吸器学会中国・四国地方会, Dec. 2023.
13.	Chisato Tonoiso, 梶野晃未, Motoharu Sasaki, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima and Masafumi Harada : 放射線治療効果を検出するMRI Radiomics特徴量の探索, 第139回日本医学放射線学会中国・四国地方会, Dec. 2023.
14.	Akiko Kubo, Chisato Tonoiso, Takashi Kawanaka, Shunsuke Furutani, Yoshiteru Ueno, Yoshito Kusuhara, Tomoharu Fukumori, Hitoshi Ikushima and Masafumi Harada : 高リスク前立腺癌外照射併用小線源治療の後方視的検討, 日本放射線腫瘍学会第36回学術大会, Dec. 2023.
15.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Masafumi Harada and Hitoshi Ikushima : 小線源治療を用いたMulticatheter法によるHypofractionated APBIの初期導入経験, 日本放射線腫瘍学会第36回学術大会, Dec. 2023.
16.	Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima and Masafumi Harada : 中枢神経に再発を来した眼内悪性リンパ腫の2例, 日本放射線腫瘍学会第36回学術大会, Dec. 2023.
17.	阿部祐也, Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, 行重佐和香, Kazumasa Okumura, Naoki Miyamoto, Masakazu Goto, Hiroaki Toba, Takashi Kawanaka and Hiromitsu Takizawa : 顔面のしびれを契機に発見された頭蓋底骨転移に対し放射線治療が有効であった1例, 第20回日本乳癌学会中国四国地方会, Sep. 2023.
18.	Takashi Kawanaka, Akiko Kubo, 外礒千智, 川中妙子, Hitoshi Ikushima and Masafumi Harada : Multicatheter法を用いたHypofractionated Accelerated Partial Breast Irradiationの初期経験, 日本放射線腫瘍学会小線源治療部会第25回学術大会, May 2023.
19.	竹内秀真, Motoharu Sasaki, 山下恭, Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, 下窪康史, 櫻川加奈子 and Hitoshi Ikushima : Deformable image registrationを用いた子宮頸がん放射線治療の合算線量評価, 日本放射線腫瘍学会小線源治療部会第25回学術大会, May 2023.
20.	Yuka Hiroshima, Takayoshi Shinya, Hitoshi Ikushima, Youichi Otomi, Hideki Otsuka, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Yasushi Takagi and Masafumi Harada : Multi-modality Imaging for the Patients with Metastatic Brain Tumors After Stereotactic Irradiation, The 82nd Annual Meeting of the Japan Radiological Society, Apr. 2023.
21.	平田圭市郎, Hiroyuki Ueda, takanori miyake, takanori kashihara, Yasuyuki Okada, Hironori Tanaka, hironori wada, Yasuteru Fujino, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Takashi Kawanaka, Hitoshi Ikushima, Yoshimi Bando, Yasushi Sato and Tetsuji Takayama : 切除不能・再発膵神経内分泌腫瘍(pancreatic neruoendocrine neoplasm:P-NEN)に対する集学的治療による治療成績の向上., 第109回日本消化器病学会総会, Apr. 2023.
22.	akinari kasai, Jinsei Miyoshi, Akihiro Haga, Takashi Kawanaka and Hiroshi Miyamoto : CT画像に基づいたAI機械学習モデルによる食道扁平上皮癌に対する化学放射線療法の効果予測., 第20回日本臨床腫瘍学会学術集会, Mar. 2023.
23.	Ryota Mitsuhashi, Takayoshi Shinya, Hideaki Enomoto, Youichi Otomi, Hideki Otsuka, Masafumi Harada, Seiji Iwamoto, Takashi Kawanaka, Hiroaki Toba, Hiromitsu Takizawa, Yoshimi Bando and Hisanori Uehara : 前縦隔に発生したmyxofibrosarcomaの一例, 第137回日本医学放射線学会中国・四国地方会, Dec. 2022.
24.	Yohjiroh Sunada, Takayoshi Shinya, Youichi Otomi, Youichi Otomi, Michiko Kubo, Hideki Otsuka, Masafumi Harada, Takashi Kawanaka, Yuishin Izumi, 安積麻衣, Kohhei Nakajima and Yasushi Takagi : F-18 FDG PET/CTにて多発性の神経根集積を認めた悪性リンパ腫の一例, 第137回日本医学放射線学会中国・四国地方会, Dec. 2022.
25.	Takashi Kawanaka, Chisato Tonoiso, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : 再度の乳房加速部分照射を行った温存乳房内再発の1例, 日本放射線腫瘍学会第35回学術大会, Nov. 2022.
26.	Takashi Kawanaka, Chisato Tonoiso, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : APBI臨床における最新の知見(SAVIハイブリッド照射ほか), 第11回WASAVlsの会, Jul. 2022.
27.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Hitoshi Ikushima and Masafumi Harada : SAVIアプリケーターと乳房部分切除後の切離腔の検討とその改善方法, 第30回日本乳癌学会学術総会, Jun. 2022.
28.	Akiko Kubo, Hitoshi Ikushima, Takashi Kawanaka, Chisato Tonoiso and Masafumi Harada : 子宮頸癌放射線治療における標的体積内同時ブースト(SIB)併用についての試み, 第136回日本医学放射線学会中国・四国地方会, Jun. 2022.
29.	Akiko Kubo, Hitoshi Ikushima, Chisato Tonoiso and Takashi Kawanaka : 当院でのVenezia applicatorによる子宮頸がん小線源治療の使用経験, 日本放射線腫瘍学会小線源治療部会第24回学術大会, May 2022.
30.	Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima and 原田雅史 : 乳房の照射後に発生した放射線誘発腫瘍の一例, 日本放射線腫瘍学会第34回学術大会, Nov. 2021.
31.	Akiko Kubo, Hitoshi Ikushima, Takashi Kawanaka, Chisato Tonoiso, Takaharu Kudoh and 原田雅史 : 子宮頸癌化学放射線治療後の照射野内リンパ節転移についての検討, 日本放射線腫瘍学会第34回学術大会, Nov. 2021.
32.	Akinari Kasai, Jinsei Miyoshi, Akihiro Haga, Takashi Kawanaka, Koichi Okamoto, Naoki Muguruma, Yasushi Sato and Tetsuji Takayama : CT-based AI radiomics model for predicting complete response and progression free survival of chemoradiothearapy in ESCC., 第80回日本癌学会学術総会, Oct. 2021.
33.	Hitoshi Ikushima, Tamaki Otani, Hideki Otsuka, Takashi Kawanaka, Akiko Kubo and 外磯千智 : 放射線治療における18F-3'-deoxy-3'-fluorothymidine の有用性, 第134回日本医学放射線学会中国四国地方会, Jun. 2021.
34.	Akiko Kubo, Hitoshi Ikushima, 外磯千智, Takashi Kawanaka, 下窪康史 and 櫻川加奈子 : Venezia applicatorによる子宮頸がん小線源治療の初期経験, 日本放射線腫瘍学会小線源治療部会第23回学術大会, May 2021.
35.	Takaharu Kudoh, Akihiro Haga, Motoharu Sasaki, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani and Hitoshi Ikushima : Radiomicsの手法を用いたPETによる舌癌頸部リンパ節転移の予測, 日本放射線腫瘍学会第33回学術大会, Oct. 2020.
36.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso and Hitoshi Ikushima : Single-entry applicatorとinterstitial needleを併用した小線源治療によるAPBIの1例, 日本放射線腫瘍学会第33回学術大会, Oct. 2020.
37.	Takashi Kawanaka : Withコロナ・Postコロナ時代のSAVIの普及, Working Group of APBI with SAVIs in Japan, Jun. 2020.
38.	Takashi Kawanaka : 当院にて行ったHybrid APBIの1例, 日本放射線腫瘍学会第22回小線源治療部会学術大会, May 2020.
39.	Akiko Kubo, Hitoshi Ikushima, Chisato Tonoiso, Takashi Kawanaka, Shunsuke Furutani and Masafumi Harada : 腋か領域を含めた乳癌術後照射における放射線肺臓炎の検討, 日本放射線腫瘍学会第32回学術大会, Nov. 2019.
40.	Chisato Tonoiso, Akihiro Haga, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh, Hitoshi Ikushima and Masafumi Harada : 子宮頸部扁平上皮癌における予後因子の検討, 日本放射線腫瘍学会第32回学術大会, Nov. 2019.
41.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 当院におけるSAVIアプリケータを用いたAPBIの術式と整合性についての検討, 日本放射線腫瘍学会第32回学術大会, Nov. 2019.
42.	Shunsuke Furutani, Hitoshi Ikushima, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka and Masafumi Harada : 非小細胞肺癌能転移に対する全脳照射の局所制御に関する検討, 日本放射線腫瘍学会第32回学術大会, Nov. 2019.
43.	外礒千智, Akihiro Haga, 高橋彩加, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 治療前MRI画像を用いた子宮頸癌予後因子の検討, 日本放射線腫瘍学会第31回学術大会, Oct. 2018.
44.	Takaharu Kudoh, 高橋彩加, 外礒千智, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani and Hitoshi Ikushima : 当院における放射線性骨壊死に関する臨床的研究, 日本放射線腫瘍学会第31回学術大会, Oct. 2018.
45.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, 高橋彩加, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : ビタミンA含有軟膏を予防的塗布した全乳房照射症例の検討, 日本放射線腫瘍学会第31回学術大会, Oct. 2018.
46.	高橋彩加, Shunsuke Furutani, 外礒千智, Akiko Kubo, Takashi Kawanaka, Akiko Abe, Masato Nishimura, Takaharu Kudoh, Hitoshi Ikushima and Masafumi Harada : 子宮頸部及び腟の異型性・上皮内癌に対する高線量率小線源治療, 日本放射線腫瘍学会第31回学術大会, Oct. 2018.
47.	Akiko Kubo, 高橋彩加, 外礒千智, Takaharu Kudoh, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 子宮頸癌根治的化学放射線治療後の仙骨不全骨折についての検討, 日本放射線腫瘍学会第31回学術大会, Oct. 2018.
48.	Akiko Kubo, 高橋彩加, Chisato Tonoiso, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 子宮頸部扁平上皮癌放射線治療後局所残存を疑った症例, 第54回日本医学放射線学会秋季臨床大会, Oct. 2018.
49.	Chisato Tonoiso, 高橋彩加, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh, Hitoshi Ikushima and Masafumi Harada : 乳房原発悪性リンパ腫の1 例, 第54回日本医学放射線学会秋季臨床大会, Oct. 2018.
50.	Akiko Kubo, 高橋彩加, Chisato Tonoiso, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 子宮頚部扁平上皮癌放射線治療後局所残存を疑った症例, Oct. 2018.
51.	高橋彩加, Takashi Kawanaka, Chisato Tonoiso, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 乳癌放射線治療後の難治性潰瘍に対して胸壁再建を施行した1 例, 第54回日本医学放射線学会秋季臨床大会, Oct. 2018.
52.	Shunsuke Furutani, Hitoshi Ikushima, 外磯千智, Akiko Kubo, Takashi Kawanaka, Hidehisa Mori, Tomoharu Fukumori, Minoru Sakama and Masafumi Harada : 前立腺癌I-125シード治療におけるセラストランドの使用経験(オンコシードと比較して), 日本放射線腫瘍学会小線源治療部会第20回学術大会, Jun. 2018.
53.	Akiko Kubo, Hitoshi Ikushima, Chisato Tonoiso, Takashi Kawanaka and Shunsuke Furutani : Image registration softwareを用いた子宮頸癌放射線治療の統合線量評価の検討, Jun. 2018.
54.	高橋彩加, Shunsuke Furutani, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima, Masafumi Harada, Akiko Abe and Masato Nishimura : 子宮頸部及び膣の異形成・上皮内癌に対する高線量率小線源治療, Jun. 2018.
55.	三橋遼太, Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, 高橋彩加, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 子宮頚部小細胞癌に対して放射線治療を行った2症例, Jun. 2018.
56.	Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 放射線治療を施行した乳房原発悪性リンパ腫の1例, May 2018.
57.	Takashi Kawanaka, Akiko Kubo, 外礒千智, 川中妙子, Hitoshi Ikushima and Masafumi Harada : 乳癌からの転移性腰椎腫瘍に対してVMAT を用いた再照射を行った1例, 第26回日本乳癌学会学術総会, May 2018.
58.	Shunsuke Furutani, Hitoshi Ikushima, 外磯千智, Akiko Kubo, Takashi Kawanaka and Masafumi Harada : 前立腺癌I-125シード治療におけるセラストランドの使用経験, 第129回日本医学放射線学会中国・四国地方会, Dec. 2017.
59.	Shunsuke Furutani, Hitoshi Ikushima, 外礒千智, Akiko Kubo, Takashi Kawanaka and Masafumi Harada : 肺癌脳転移に対する全脳照射の局所制御に関する検討, 日本放射線腫瘍学会第30回学術大会, Nov. 2017.
60.	外礒千智, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh and Hitoshi Ikushima : 当院における外耳癌の治療成績, 日本放射線腫瘍学会第30回学術大会, Nov. 2017.
61.	Akiko Kubo, 外礒千智, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh, Hitoshi Ikushima and Masafumi Harada : Image registration softwareを用いた子宮頸がん放射線治療の統合線量評価, 日本放射線腫瘍学会第30回学術大会, Nov. 2017.
62.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, 外礒千智, Hitoshi Ikushima and Masafumi Harada : 子宮頸癌根治的放射線治療における組織内照射併用腔内照射での線量分布に関する検討, 日本放射線腫瘍学会第30回学術大会, Nov. 2017.
63.	Tomoharu Fukumori, Hidehisa Mori, Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 高リスク限局性前立腺癌に対する I-125 密封小線源療法の治療成績と生化学的再発予測因子の検討, 第55回日本癌治療学会学術集会, Oct. 2017.
64.	外礒千智, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani and Hitoshi Ikushima : 子宮頸部小細胞癌の1例, 第53回日本医学放射線学会秋季臨床大会, Sep. 2017.
65.	外礒千智, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 当院における聴器癌の治療成績, 第127回日本医学放射線学会中国・四国地方会, Dec. 2016.
66.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : Sequential radioactive iodine treatment and intensity modulated radiotherapy:a case repot, The 29th Annual Meeting of the Japanese Society for Radiation Oncology, Nov. 2016.
67.	Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : Presumed abscopal effect of radiation on bone and brain metastases of lung cancer:a case report, The 29th Annual Meeting of the Japanese Society for Radiation Oncology, Nov. 2016.
68.	細谷未来, Motoharu Sasaki, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo, Takaharu Kudoh and Hitoshi Ikushima : Dosimetric comparison of VMAT and 3DCRT in patients with cervical cancer, The 29th Annual Meeting of the Japanese Society for Radiation, Nov. 2016.
69.	Shunsuke Furutani, Hitoshi Ikushima, Takashi Kawanaka, Akiko Kubo, 高橋彩加, 宮本加奈子, 新井悠太, 長瀬紗季 and Masafumi Harada : 多発性脳転移に対するVMATを用いた分割定位放射線治療の治療成績, 日本放射線腫瘍学会, Nov. 2016.
70.	Takaharu Kudoh, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani and Hitoshi Ikushima : 頭頸部癌に対するIMRTにおける予防的頸部CTV設定の妥当性の検証, 日本放射線腫瘍学会第29回学術大会, Nov. 2016.
71.	Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : アブスコパル効果と思われる治療経過を示した肺癌の1症例, 第54回日本癌治療学会学術集会, Oct. 2016.
72.	Takashi Kawanaka, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 甲状腺乳頭癌頸部リンパ節転移に対してI-131による内容療法とIMRTを逐次併用した1症例, 第54回日本癌治療学会学術集会, Oct. 2016.
73.	Takashi Kawanaka : RAI不応性甲状腺癌の考え方, Thyroid cancer update, Sep. 2016.
74.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 癌脳転移に対する放射線治療後のに開頭手術を施行した症例の検討, 第24回乳癌学会学術総会, Jun. 2016.
75.	Takashi Kawanaka : ブラキセラピー単独治療の適応 -中リスクの長期成績から-, Brachytherapy Update 2016 in Osaka, May 2016.
76.	高橋彩加, Shunsuke Furutani, Seiji Iwamoto, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima, Masafumi Harada and Takaharu Kudoh : 鼻副鼻腔癌に対する強度変調放射線治療の初期経験, 日本医学放射線学会中国四国地方会, Dec. 2015.
77.	Takaharu Kudoh, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani and Hitoshi Ikushima : Necessity of postoperative radiation therapy of contralateral neck for later alized oral squamous cell carcinoma, 日本放射線腫瘍学会第28回学術大会, Nov. 2015.
78.	Shunsuke Furutani, Akiko Kubo, Takashi Kawanaka, Takaharu Kudoh and Hitoshi Ikushima : Clinical outcomes of volumetric modulated arc therapy for multiple brain metastases, 日本放射線腫瘍学会, Nov. 2015.
79.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, 高橋彩加, Hitoshi Ikushima and Masafumi Harada : Intensity modulated radiation therapy for cervical cancer: Potential efficacy for reducing the adverse pelvic bone event, 日本放射線腫瘍学会, Nov. 2015.
80.	Tomoharu Fukumori, Hidehisa Mori, Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, 大豆本圭, 津田恵, Yoshito Kusuhara, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : I-125密封小線源療法のPSA再発症例の臨床的検討, 第53回日本癌治療学会学術集会, Oct. 2015.
81.	Takashi Kawanaka, Shunsuke Furutani, Akiko Kubo, Tomoharu Fukumori, Hitoshi Ikushima and Masafumi Harada : 当院におけるI-125シード永久刺入療法を行った前立腺癌の長期成績の検討, 第51回日本医学放射線学会秋季臨床大会, Oct. 2015.
82.	Takashi Kawanaka : 骨転移治療の動向と外照射併用89-Sr内用療法, 第40回愛媛核医学懇話会, Sep. 2015.
83.	Takashi Kawanaka, Akiko Kubo and Masafumi Harada : 放射線照射後の難治性皮膚潰瘍の一例, 第23回日本乳癌学会学術総会, Jul. 2015.
84.	小畑祐太, 三宅裕司, Motoharu Sasaki, 下窪靖史, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo, Takaharu Kudoh and Hitoshi Ikushima : 子宮頸癌腔内照射におけるリンパ節領域の線量評価, 日本放射線腫瘍学会小線源治療部会, Jun. 2015.
85.	Takashi Kawanaka, Shunsuke Furutani, Akiko Kubo, Tomoharu Fukumori, Hitoshi Ikushima, Hiro-omi Kanayama and Masafumi Harada : 当院で長期経過観察をした前立腺癌I-125シード永久挿入療法の検討, 日本放射線腫瘍学会小線源部会, Jun. 2015.
86.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 転移性脳腫瘍に対する定位放射線治療に関する検討, 第123回日本放射線学会中国四国地方会, Dec. 2014.
87.	Kyo Yamashita, Hitoshi Ikushima, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Kyosuke Osaki, Takaharu Kudoh, Masahide Tominaga and 仁木孝明 : 放射線治療に携わるスタッフのストレス状況∼徳島県の場合∼, 日本放射線腫瘍学会27回学術大会, Dec. 2014.
88.	Takaharu Kudoh, Motoharu Sasaki, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani and Hitoshi Ikushima : 頭頸部癌放射線治療中の転移リンパ節のサイズ変化と制御との関連, 日本放射線腫瘍学会27回学術大会, Dec. 2014.
89.	Shunsuke Furutani, Akiko Kubo, Takashi Kawanaka, Takaharu Kudoh, Hitoshi Ikushima, Tomoharu Fukumori and Hiro-omi Kanayama : 5年以上経過した前立腺癌I-125シード治療症例における線量増加の有効性と安全性の検討, 日本放射線腫瘍学会27回学術大会, Dec. 2014.
90.	Takashi Kawanaka, Shunsuke Furutani, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : 転移性骨腫瘍に対する外部方射線療法と塩化ストロンチウム-89併用に関する検討, 日本放射線腫瘍学会27回学術大会, Dec. 2014.
91.	Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani and Hitoshi Ikushima : 子宮頸癌根治的科学放射線化学療法後のFDG集積と予後との関連, 日本放射線腫瘍学会27回学術大会, Dec. 2014.
92.	Noboru Isobe, Motoharu Sasaki, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo and Takaharu Kudoh : 子宮頸癌に愛するIMRTの有効性ー骨盤骨線量の検討ー, 日本放射線腫瘍学会27回学術大会, Dec. 2014.
93.	Takashi Kawanaka, Shunsuke Furutani, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : 転移性骨腫瘍に対する外部方射線療法と塩化ストロンチウム-89併用に関する検討, 第52回日本癌治療学会学術集会, Aug. 2014.
94.	Shunsuke Furutani, Hitoshi Ikushima, Akiko Kubo, Takashi Kawanaka and Masafumi Harada : 当院における原発性肺癌に対する定位放射線治療成績, 第122回日本医学放射線学会中国・四国地方会, Jun. 2014.
95.	Takashi Kawanaka, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : 食道癌術後再発に対する放射線治療症例の検討, 第34回四国食道疾患研究会, Feb. 2014.
96.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima, lto Emma and Liu Fei-Fei : 子宮頸癌細胞でUROD knockdownを用いた放射線化学療法に関する基礎的検討, 日本放射線腫瘍学会第26回学術大会, Oct. 2013.
97.	三宅悠太, Takashi Kawanaka, 三枝裕司, 下窪康史, Motoharu Sasaki, 岸太郎, Shunsuke Furutani, Akiko Kubo, Takaharu Kudoh and Hitoshi Ikushima : Cone beam CTによる3次元画像誘導小線源治療, 日本放射線腫瘍学会第26回学術大会, Oct. 2013.
98.	Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh, 尾崎享祐, Kyo Yamashita and Hitoshi Ikushima : 外陰癌大腿鼠径リンパ節転移に関する照射野の検討, 日本放射線腫瘍学会第26回学術大会, Oct. 2013.
99.	Tomoharu Fukumori, Tomokazu Senzaki, Takashi Kawanaka, Akiko Kubo, Jun-ichiro Kagawa, Masatsugu Komori, Hisaya Takahashi, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 限局性前立腺癌に対するI-125密封小線源療法のPSA再発予測因子の検討, 第48回日本がん治療学会学術集会, Sep. 2013.
100.	Hitoshi Ikushima, Akiko Kubo, Takaharu Kudoh, Takashi Kawanaka and Shunsuke Furutani : 子宮頸癌放射線治療の新展開子宮頸癌放射線治療後局所再発の診断, 第54回日本婦人科腫瘍学会学術講演会, Jul. 2013.
101.	中島和弥, Seiji Iwamoto, Takashi Kawanaka, Takaharu Kudoh, Takaharu Kudoh, Akiko Kubo, Youichi Otomi, Shunsuke Furutani, Hideki Otsuka and Hitoshi Ikushima : 頭頸部癌の化学放射線療法における11C-Methionine PETの有用性, 日本放射線腫瘍学会第26回学術大会, Jul. 2013.
102.	Hitoshi Ikushima, 三枝裕司, 下窪康史, Takashi Kawanaka, Akiko Kubo, Takaharu Kudoh, 原康男, Motoharu Sasaki, 川下徹也 and 岸太郎 : 第120回日本医学放射線学会中国・四国放射線治療懇話会, Jun. 2013.
103.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani and Hitoshi Ikushima : 子宮頸癌放射線治療後の予後予測因子としてのUROD, 日本放射線腫瘍学会第25回学術大会, Dec. 2012.
104.	Takaharu Kudoh, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo and Hitoshi Ikushima : 口腔癌の放射線治療に用いる新型マウスピースの開発, 日本放射線腫瘍学会第25回学術大会, Dec. 2012.
105.	Akiko Kubo, Shunsuke Furutani, Takashi Kawanaka, Takaharu Kudoh, 尾崎享祐, Kyo Yamashita and Hitoshi Ikushima : 子宮頸癌放射線治療後局所再発の画像診断に関する検討, 日本放射線腫瘍学会第25回学術大会, Dec. 2012.
106.	木村雅司, Akiko Kubo, Motoharu Sasaki, Yasuo Hara, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh and Hitoshi Ikushima : 放射線治療期間中に生じる標的の変化, 日本放射線腫瘍学会第25回学術大会, Dec. 2012.
107.	Hitoshi Ikushima, Youichi Otomi, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo and Takaharu Kudoh : III期局所進行非小細胞肺癌の術前導入化学放射線療法, 第119回日本医学放射線学会中国四国地方会, Dec. 2012.
108.	Akiko Kubo, Shunsuke Furutani, Takashi Kawanaka, Takaharu Kudoh, Kyosuke Osaki, Kyo Yamashita and Hitoshi Ikushima : 子宮頸癌放射線治療後局所再発の画像診断に関する検討, 日本放射線腫瘍学会第25回学術大会, Nov. 2012.
109.	Shunsuke Furutani, Takuya Saze, Yoshinori Kuwahara, 山田隆治, 市樂輝義, 篠原敏徳, 高井久司, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima and Masafumi Harada : 臨床用全自動型 I-125シード放射線強度測定システムの開発, 日本放射線腫瘍学会第14回小線源治療部会, May 2012.
110.	Akiko Kubo, Shunsuke Furutani, Takashi Kawanaka, Takaharu Kudoh, Kyosuke Osaki, Kyo Yamashita and Hitoshi Ikushima : 子宮頚癌化学放射線治療のリンパ節制御に関する検討, 日本放射線腫瘍学会第24回学術大会, Nov. 2011.
111.	Shunsuke Furutani, Hitoshi Ikushima, Maki Ohtomo, Akiko Kubo, Takashi Kawanaka, Takaharu Kudoh, Tomoharu Fukumori, Hiro-omi Kanayama and Masafumi Harada : 前立腺癌 I-125 シード単独治療における線量増加の有効性と安全性の検討, 日本放射線腫瘍学会第24回学術大会, Nov. 2011.
112.	Hitoshi Ikushima, Takaharu Kudoh, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo and Kazuya Kondo : 胸腺腫の放射線治療, 第115回日本医学放射線学会中国・四国地方会, May 2011.
113.	山崎浩実, Shunsuke Furutani, 岩河早保, Akiko Kubo, Akiko Kubo, Takashi Kawanaka and Hitoshi Ikushima : 神経膠芽腫に対するテモゾロミド併用放射線治療成績, 第115回日本医学放射線学会中国・四国地方会, Dec. 2010.
114.	Takaharu Kudoh, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo, 村上千尋, 岩河早保, 山埼浩実 and Hitoshi Ikushima : 192-Ir モールド照射時の鉛とアクリルによる遮蔽効果の検討, 日本放射線腫瘍学会第23回学術大会, Nov. 2010.
115.	村上千尋, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh, 尾崎享祐 and Hitoshi Ikushima : 子宮頸癌に対するclinical target volume 設定ガイドラインの検証, 日本放射線腫瘍学会第23回学術大会, Nov. 2010.
116.	坂東良太, Takashi Kawanaka, Takaharu Kudoh, 原康男, 佐々木幹治, Akiko Kubo, Shunsuke Furutani and Hitoshi Ikushima : 頭頚部腫瘍に対する放射線治療中の解剖学的変化に関する検討, 日本放射線腫瘍学会第23回学術大会, Nov. 2010.
117.	Akiko Kubo, Shunsuke Furutani, 山崎浩実, 岩河早保, Takaharu Kudoh, Takashi Kawanaka and Hitoshi Ikushima : 根治的化学放射線治療後再発子宮頸癌に対する救済療法の検討, 日本放射線腫瘍学会第23回学術大会, Nov. 2010.
118.	Shunsuke Furutani, Takuya Saze, Takashi Kawanaka, Akiko Kubo and Hitoshi Ikushima : シンチレーション式サーベイメーターを用いた簡易的なヨウ素125密封小線源の線源強度測定システムの検討, 日本放射線腫瘍学会小線源治療部会第12回研究会, May 2010.
119.	Shunsuke Furutani, Hitoshi Ikushima, Seiji Iwamoto, Akiko Kubo, Takashi Kawanaka, Kyosuke Osaki, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama and Hiromu Nishitani : 膀胱温存を目的とした浸潤性膀胱癌に対するTUR-Bt+動注化学放射線療法の治療成績, 第47回日本癌治療学会学術集会, Oct. 2009.
120.	Shunsuke Furutani, Hitoshi Ikushima, Kyosuke Osaki, Takashi Kawanaka, Akiko Kubo and Hiromu Nishitani : 当院における前立腺癌密封小線源療法の治療成績, 日本放射線腫瘍学会第22回学術大会, Sep. 2009.
121.	Shunsuke Furutani, Hitoshi Ikushima, Kyosuke Osaki, Takashi Kawanaka, Akiko Kubo and Hiromu Nishitani : 当院における前立腺癌術後のPSA再発に対する放射線治療成績, 日本放射線腫瘍学会第21回学術大会, Oct. 2008.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

放射線治療後の心筋障害に対する早期の定量的評価法の確立と心不全の予知 (Project/Area Number: 22K07722 )
Search by Researcher Number (20527379)

Associate Professor : Kawanaka, Takashi

Research

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)